A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

Purpose

The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.

Conditions

  • Healthy
  • Obesity
  • Overweight

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Have a hemoglobin A1c level of less than 6.5 percent (%) at screening. - Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening - Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of childbearing potential (INOCBP) Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria

  • Have obesity induced by endocrine disorders such as Cushing's syndrome or Prader Willi syndrome. - Have any of the following conditions at screening, - supine systolic blood pressure of 160 millimeter of mercury (mmHg) or greater - supine diastolic blood pressure of 100 mmHg or greater, or - resting pulse rate of greater than 95 beats per minute (bpm) or less than 45 bpm. (Note: white-coat hypertension is excluded; therefore, if a repeated measurement of blood pressure after at least 5 minutes shows values within the range, the participant can be included). - Have had any of the following within 6-months prior to screening - myocardial infarction - unstable angina - coronary artery bypass graft - percutaneous coronary intervention. (Note: diagnostic angiograms are permitted) - transient ischemic attack - cerebrovascular accident or decompensated congestive heart failure, or - New York Health Association Class III or IV heart failure. - Have serum triglyceride of 5 millimoles per liter (mmol/L) or greater (442 milligrams per deciliter [mg/dL]) at screening - Have had any exposure to glucagon-like peptide-1 (GLP-1) analogs or other related compounds within the 3 months prior to screening

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Basic Science
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LY3549492 (Treatment Group 1) 		LY3549492 administered orally.
  • Drug: LY3549492
    Administered orally
Experimental
LY3549492 (Treatment Group 2) 		LY3549492 administered orally.
  • Drug: LY3549492
    Administered orally

Recruiting Locations

Fortrea Clinical Research Unit
Daytona Beach 4152872, Florida 4155751 32117
Contact:
866-429-3700

Fortrea Clinical Research Unit
Dallas 4684888, Texas 4736286 75247
Contact:
866-429-3700

Fortrea Clinical Research Unit
Madison 5261457, Wisconsin 5279468 53704
Contact:
866-429-3700

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com